Lava Therapeutics shares hold target with Buy rating By Investing.com
On Friday, HC Wainwright maintained a Buy rating on shares of Lava Therapeutics NV (NASDAQ: LVTX), with a $6.00 price target. Lava Therapeutics, a biotechnology company, recently participated in the 2nd Annual Immune Cell Engager…